AbbVie Expands Immunology Pipeline with $200M Acquisition of Nimble Therapeutics

Acquisition Details:
AbbVie will acquire Nimble Therapeutics for $200 million upfront, with additional interim funding payments and a potential development milestone payment14.

Lead Asset:
The acquisition includes Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis and potentially inflammatory bowel diseases14.

Pipeline Expansion:
AbbVie will also gain ownership of Nimble's other pipeline assets, including an oral C5 blocker for generalized myasthenia gravis and an oral TL1A inhibitor for inflammatory bowel diseases4.

Peptide Technology:
AbbVie will acquire Nimble's proprietary peptide synthesis, screening, and optimization platform, which can produce over 100 million individual peptide compounds overnight14.

Strategic Impact:
The acquisition is part of AbbVie's strategy to rebuild and cement its long-term growth prospects, particularly in immunology, following recent setbacks and anticipated market erosion for Skyrizi and Rinvoq4.

Analyst Support:
Guggenheim Partners analysts are supportive of AbbVie's recent deals, believing they demonstrate a strategic commitment to sustaining long-term growth in immunology and neuroscience4.

Sources:

1. https://www.prnewswire.com/news-releases/abbvie-to-acquire-nimble-therapeutics-further-strengthening-immunology-pipeline-302331351.html

4. https://www.biospace.com/business/abbvie-continues-deal-making-spree-with-200m-nimble-buy